In the BioHarmony Drug Report Database

"Preview" Icon

Certolizumab pegol

Cimzia (certolizumab pegol) is an antibody pharmaceutical. Certolizumab pegol was first approved as Cimzia on 2008-04-22. It is used to treat ankylosing spondylitis, crohn disease, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tumor necrosis factor.

 

Trade Name

 

Cimzia
 

Common Name

 

certolizumab pegol
 

ChEMBL ID

 

CHEMBL1201831
 

Indication

 

ankylosing spondylitis, crohn disease, psoriatic arthritis, rheumatoid arthritis
 

Drug Class

 

Monoclonal antibodies: humanized, immunomodulating; PEGylated compounds

Image (chem structure or protein)

Certolizumab pegol structure rendering